

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

UMAÑA *et al.*

Appl. No.: 10/633,697

Filed: August 5, 2003

For: **Glycosylation Engineering of
Antibodies for Improving
Antibody-Dependent Cellular
Cytotoxicity**

Confirmation No.: 5455

Art Unit: 1636

Examiner: Guzo, D.

Atty. Docket: 1975.0010005/TJS/T-M

Amendment and Reply Under 37 C.F.R. § 1.111 and § 1.114

Mail Stop RCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the final Office Action dated September 10, 2007, Applicants submit the following Amendment and Remarks. This Amendment is accompanied by a Request for Continued Examination. Applicants respectfully request that the finality of the Office Action be withdrawn. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on page 3, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (C) Starting on page 11, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.